Publication | Closed Access

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

Rheumatoid DisorderRheumatologyAnti-inflammatoryMedicineClinical TrialsKinase 2Inflammatory Rheumatic DiseasePharmacotherapyBlinded Phase 2BPharmacologyNovel TherapyRheumatoid Arthritis